121 related articles for article (PubMed ID: 21543173)
1. Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors.
Saito T; Yamasaki F; Kajiwara Y; Abe N; Akiyama Y; Kakuda T; Takeshima Y; Sugiyama K; Okada Y; Kurisu K
Eur J Radiol; 2012 Aug; 81(8):1863-9. PubMed ID: 21543173
[TBL] [Abstract][Full Text] [Related]
2. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.
Spampinato MV; Smith JK; Kwock L; Ewend M; Grimme JD; Camacho DL; Castillo M
AJR Am J Roentgenol; 2007 Jan; 188(1):204-12. PubMed ID: 17179366
[TBL] [Abstract][Full Text] [Related]
3. Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas.
Spampinato MV; Schiarelli C; Cianfoni A; Giglio P; Welsh CT; Bisdas S; Rumboldt Z
Neuroradiol J; 2013 Aug; 26(4):385-95. PubMed ID: 24007727
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging.
Yoon HJ; Ahn KJ; Lee S; Jang JH; Choi HS; Jung SL; Kim BS; Jeun SS; Hong YK
Neuroradiology; 2017 Jul; 59(7):665-675. PubMed ID: 28550465
[TBL] [Abstract][Full Text] [Related]
5. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
[TBL] [Abstract][Full Text] [Related]
6. Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes.
Emblem KE; Scheie D; Due-Tonnessen P; Nedregaard B; Nome T; Hald JK; Beiske K; Meling TR; Bjornerud A
AJNR Am J Neuroradiol; 2008 Oct; 29(9):1664-70. PubMed ID: 18583405
[TBL] [Abstract][Full Text] [Related]
7. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.
Xu M; See SJ; Ng WH; Arul E; Back MF; Yeo TT; Lim CC
Neurosurgery; 2005 May; 56(5):919-26; discussion 919-26. PubMed ID: 15854239
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.
Sunwoo L; Choi SH; Yoo RE; Kang KM; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Park SW; Sohn CH; Won JK; Park SH; Kim IH
Neuroradiology; 2015 Nov; 57(11):1111-20. PubMed ID: 26232204
[TBL] [Abstract][Full Text] [Related]
9. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging.
Whitmore RG; Krejza J; Kapoor GS; Huse J; Woo JH; Bloom S; Lopinto J; Wolf RL; Judy K; Rosenfeld MR; Biegel JA; Melhem ER; O'Rourke DM
J Neurosurg; 2007 Sep; 107(3):600-9. PubMed ID: 17886561
[TBL] [Abstract][Full Text] [Related]
10. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
Law M; Oh S; Johnson G; Babb JS; Zagzag D; Golfinos J; Kelly PJ
Neurosurgery; 2006 Jun; 58(6):1099-107; discussion 1099-107. PubMed ID: 16723889
[TBL] [Abstract][Full Text] [Related]
11. Primary and metastatic intraaxial brain tumors: prospective comparison of multivoxel 2D chemical-shift imaging (CSI) proton MR spectroscopy, perfusion MRI, and histopathological findings in a group of 159 patients.
Bendini M; Marton E; Feletti A; Rossi S; Curtolo S; Inches I; Ronzon M; Longatti P; Di Paola F
Acta Neurochir (Wien); 2011 Feb; 153(2):403-12. PubMed ID: 21165751
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
[TBL] [Abstract][Full Text] [Related]
13. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
Thomsen H; Steffensen E; Larsson EM
Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
[TBL] [Abstract][Full Text] [Related]
14. Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas.
Young R; Babb J; Law M; Pollack E; Johnson G
J Magn Reson Imaging; 2007 Oct; 26(4):1053-63. PubMed ID: 17896374
[TBL] [Abstract][Full Text] [Related]
15. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging.
Hakyemez B; Erdogan C; Ercan I; Ergin N; Uysal S; Atahan S
Clin Radiol; 2005 Apr; 60(4):493-502. PubMed ID: 15767107
[TBL] [Abstract][Full Text] [Related]
16. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
[TBL] [Abstract][Full Text] [Related]
17. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
Fayed N; Dávila J; Medrano J; Olmos S
Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
[TBL] [Abstract][Full Text] [Related]
18. Astrocytic tumour grading: a comparative study of three-dimensional pseudocontinuous arterial spin labelling, dynamic susceptibility contrast-enhanced perfusion-weighted imaging, and diffusion-weighted imaging.
Xiao HF; Chen ZY; Lou X; Wang YL; Gui QP; Wang Y; Shi KN; Zhou ZY; Zheng DD; Wang DJ; Ma L
Eur Radiol; 2015 Dec; 25(12):3423-30. PubMed ID: 26002128
[TBL] [Abstract][Full Text] [Related]
19. Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion weighted imaging.
Xu JL; Shi DP; Dou SW; Li YL; Yan FS
J Med Imaging Radiat Oncol; 2011 Dec; 55(6):587-94. PubMed ID: 22141606
[TBL] [Abstract][Full Text] [Related]
20. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
